Prothena to Report Second Quarter 2022 Financial Results on August 8th
01 Agosto 2022 - 5:05PM
Prothena to Report Second Quarter 2022 Financial Results on August
8th
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
biotechnology company with a robust pipeline of investigational
therapeutics built on protein dysregulation
expertise, announced today that it will report its second
quarter and first six months of 2022 financial results on Monday,
August 8, 2022 after the close of the U.S. financial markets.
Consistent with past practice, the Company will
not be conducting a conference call in conjunction with this
financial results release on August 8.
About Prothena
Prothena Corporation plc is a late-stage
clinical biotechnology company with expertise in protein
dysregulation and a pipeline of investigational therapeutics with
the potential to change the course of devastating neurodegenerative
and rare peripheral amyloid diseases. Fueled by its deep scientific
expertise built over decades of research, Prothena is advancing a
pipeline of therapeutic candidates for a number of indications and
novel targets for which its ability to integrate scientific
insights around neurological dysfunction and the biology of
misfolded proteins can be leveraged. Prothena’s pipeline includes
both wholly-owned and partnered programs being developed for the
potential treatment of diseases including AL amyloidosis, ATTR
amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number
of other neurodegenerative diseases. For more information, please
visit the Company’s website at www.prothena.com and
follow the Company on Twitter @ProthenaCorp.
Contacts:
InvestorsJennifer Zibuda,
Director, Investor Relations & Communications650-837-8535,
jennifer.zibuda@prothena.com
MediaEric Endicott, Senior Vice
President, Corporate Affairs650-448-3670,
eric.endicott@prothena.com
Prothena (LSE:0Y3M)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Prothena (LSE:0Y3M)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
Notícias em tempo-real sobre Prothena Corporation Plc da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de